(Date:8/28/2008)... associated with increased plaque , , TH...earchers has described hourly changes in a protein...n Alzheimer,s disease. , In a 2005 study, the ...d to brain cell communication in a mouse model of ... increased, so did amyloid beta. When there was re...
(Date:8/28/2008)...., the leading innovator and provider of email and...on support, compliance, and storage management, to...l Archive has won MSExchange.org,s prestigious Rea...rise Email Archive is an on-site software solution...5.5 through 2007. , Milpi...
(Date:8/28/2008)...uncil for Continuing Medical Education (ACCME) has...American Pathologists (CAP) the status of Accredit...g medical education for physicians. , ...8 -- The Accreditation Council for Continuing Medi...vision of the www.cap.org [College of American P...
(Date:8/28/2008)...e Users to Learn about Each Candidate,s Health Car... Miami, FL (PRWEB) August 28, 2008 -- Health...leader in local healthcare provider search, announ...Obama and McCain on Health Care" ( http://dec...ve voting guide for the 2008 U.S. presidential ele...
Breaking Medicine News(10 mins):Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 2Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 3Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 4Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 5Health News:College of American Pathologists' Education Division Receives Top Honor 2Health News:College of American Pathologists' Education Division Receives Top Honor 3Health News:HealthCare.com Launches HealthDecision '08: Obama and McCain on Health Care 2Health News:HealthCare.com Launches HealthDecision '08: Obama and McCain on Health Care 3...a health care reform plan in January next year tha...ons of Pennsylvanians who lack coverage. Governor ...s, hospital infections etc. The plan, which was u... latest health care initiatives that have been sup...
...es of India migrate to the industrialized regions ... end up with AIDS.// Bihari migrants are estimated... usually work as taxi drivers, mechanics, security...s big cities. "I just did not think about what I ...
...hers have opined on the basis of recent studies th...not guarantee the prevention of a relapse. AC/T, ...e in preventing a relapse as compared to CEF, whic... in this regard. A new experimental chemotherapy p...
...technology will provide soft loans to pharmaceutic...gs and carry out clinical trials, the company said... is under the science and technology ministry, Ran...opment of therapeutic drugs for anti-infective and...
Other Medicine News:Health News:Poverty Fuels HIV In Poor Indian States 2(Date:8/28/2008)... --, - Results Further Support the Clinical Profi...nt to Improve the Survival of Patients,With Hormon...OSE: ALGETA), the Norwegian cancer therapeutics co...of its BC1-03 Phase II pain,palliation study was m...haradin in patients with painful bone metastases c...
(Date:8/27/2008)...FirstCall/ --, - Oralair(R) Grasses 300IR Highly ...dy Conducted in an Allergen Challenge Chamber, St...lts of a new study,conducted in an Allergen Challe...es included 86 adult patients exposed to,grass pol...1 week, 1 month,2 and 4 months without a titratio...
(Date:8/26/2008)...Semafore Pharmaceuticals Inc.,announced data prese...eted,Therapies in Cancer in Washington, D.C., show...-targeted PI3 kinase (PI3K) inhibitor SF1126, by,b...t of a very powerful pathway, the PI3/AKT /mTOR pa...cancer. Studies have shown that by,inhibiting this...
(Date:8/26/2008)...e-FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today...ta,from the CUSTOM II trial was published in the m...oIntervention. The lead author of the article was,...Center Utrecht, Utrecht,The Netherlands on behalf...ites across Europe., The one-year CUSTOM II trial...
Breaking Medicine Technology:Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Elbow Injuries on Rise Among Young Athletes 23884 1Elbow Injuries on Rise Among Young Athletes 23884 2Elbow Injuries on Rise Among Young Athletes 23884 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 11FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 1FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 2FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 3Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 1Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 2Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 3... drug interaction,with paliperidone ER, SAN DIEGO,... of,paliperidone extended-release (ER) tablets, bl...n with a common antidepressant,according to new d... the American Psychiatric Association. Paroxetine,...is an antidepressant known to,interact with severa...
...us Stent, BARCELONA, Spain, May 23, 2007 /PRNewswi...-engineered R stent compares favorably,to that of ...osis,is minimized with the Genous stent, according...sented today by Robbert de,Winter, M.D., Ph.D., at...m more than 120 sites in 29 countries, follow-up,d...
Other Medicine Technology:Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 2Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 3Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 4Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 5Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 6Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches.
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches.
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches.
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches.
Medicine Products: